- Opinion
- [Reporter's View] Slow but steady wins the race
- by Whang, byung-woo Feb 4, 2025 05:55am
- The Korean government has finally launched the National Bio Commission. The launch of this proper control tower has come several years after the government declared the bio-health industry as a national strategic industry. The news of its launch is encouraging, considering how the launch of the committee itself was almost stranded due to
- Company
- Lixiana leads the DOAC market..generics make advances
- by Kim, Jin-Gu Feb 4, 2025 05:55am
- Daiichi Sankyo's Lixiana (edoxaban) is further solidifying its dominance in the direct-acting oral anticoagulant (DOAC) market. Prescriptions grew 12% year-on-year, and its share of the total market expanded to 45%. Sales of Eliquis (apixaban) and Xarelto (rivaroxaban), on the other hand, have faltered. Eliquis saw its first year-over-
- Policy
- 3-way race starts in faslodex mkt with new generic entry
- by Lee, Tak-Sun Feb 3, 2025 05:52am
- A new generic company entered the fulvestrant drug market that has been a battle between the original’s owner AstraZeneca and the first generic developer Boryung. The new entrant, Korus Pharm, will spark three-way competition in the market with its product being reimbursed this month. According to industry sources on the 31st, Korus
- Company
- ROS1 targeted cancer drug 'Augtyro' nearing mkt entry
- by Eo, Yun-Ho Feb 3, 2025 05:52am
- The ROS1-targeting anticancer drug, 'Augtyro,' is expected to be commercialized in South Korea. According to industry sources, Bristol Myers Squibb (BMS) Korea is close to receiving approval from the Ministry of Food and Drug Safety (MFDS) for Augtyro (repotrectinib), an anticancer drug that can be used regardless of cancer types. This
- Policy
- Will external reference pricing reevals be further delayed?
- by Lee, Jeong-Hwan Feb 3, 2025 05:52am
- The Ministry of Health and Welfare plans to concentrate on advancing the regulations on the post-management of generic drug pricing that are being redundantly implemented in Korea. Regarding the introduction of the external reference pricing that has been gaining industry-wide attention, the MOHW reaffirmed its stance on its necessity, but th
- Company
- Samsung Bioepis loses Eylea appeal trial in the US
- by Cha, Jihyun Feb 3, 2025 05:52am
- The U.S. market entry of 'Eylea' biosimilar, a treatment for eye diseases, from Samsung Bioepis is stalled. The company recently lost a trial of appeal in addition to the previous motion filed by the developer for a preliminary injunction over a sales ban on an item. According to the biotechnology industry sources on January 31, the United S
- Company
- Jardiance is reimbursed for HFpEF
- by Whang, byung-woo Feb 3, 2025 05:52am
- The SGLT2 inhibitor Jardiance (empagliflozin) has been granted reimbursement across the full spectrum of heart failure in Korea, increasing its influence in the market. Boehringer Ingelheim Korea announced on the 31st that its drug will be granted reimbursement as of February 1st, under the Ministry of Health and Welfare notifications, fo
- Company
- ALS drug Qalsody to be commercialized in Korea
- by Eo, Yun-Ho Jan 31, 2025 05:56am
- Commercialization of the new drug ‘Qalsody’ for amyotrophic lateral sclerosis is expected in Korea. According to industry sources, Qalsody (tofersen), Biogen’s drug indicated for the treatment of amyotrophic lateral sclerosis (ALS) associated with a mutation in the Superoxide Dismutase 1 (OD1) gene mutation, is undergoing a review for
- Company
- Epkinly may be prescribed in general hospitals in KOR
- by Eo, Yun-Ho Jan 31, 2025 05:56am
- Epkinly, an innovative bispecific antibody drug that binds to T cells, may now be prescribed in general hospitals in Korea. According to industry sources, AbbVie Korea’s Epstein-Barr virus (EBV)-associated diffuse large B-cell lymphoma (DLBCL) treatment Epkinly (epcoritamab) has recently passed the drug committee (DC) review of Asan Medi
- Company
- 'Latuda,' the new schizophrenia drug, can be prescribed
- by Eo, Yun-Ho Jan 31, 2025 05:56am
- 'Latuda,' a treatment for schizophrenia, becomes available for prescription at general hospitals. According to industry sources, Bukwang Pharmaceutical's Latuda (lurasidone) has passed the drug committees of tertiary general hospitals, including Samsung Medical Center, Seoul National University Hospital, and Severance Hospital in Sinchon
